Thiazole derivatives as A2b antagonists

Details for Australian Patent Application No. 2005206290 (hide)

Owner Novartis AG

Inventors Taylor, Roger John; Press, Neil John

Agent Davies Collison Cave

Pub. Number AU-B-2005206290

PCT Pub. Number WO2005/070926

Priority 0401336.3 21.01.04 GB

Filing date 20 January 2005

Wipo publication date 4 August 2005

Acceptance publication date 4 December 2008

International Classifications

C07D 417/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

27 July 2006 PCT application entered the National Phase

  PCT publication WO2005/070926 Priority application(s): WO2005/070926

4 December 2008 Application Accepted

  Published as AU-B-2005206290

2 April 2009 Standard Patent Sealed

12 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005206291-Lawsonia intracellularis subunit vaccines

2005206289-Indol-alanine derivatives as selective S1P4-agonists